Reissuing the sigma receptors for SARS-CoV-2

Yeşilkaya, Ümit Haluk; Balcıoğlu, Yasin Hasan; Sahin, Serhat

doi:10.1016/j.jocn.2020.08.014

Cited by 13 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various receptors could be involved in neurotropism and neuronal cell entry of SARS-CoV-2 ( Armocida et al, 2020 ). Sigma receptors are widely expressed in the CNS ( Yesilkaya et al, 2020 ). Downregulation of S1R protein expression impairs initiation of hepatitis C virus (HCV) RNA replication in human hepatoma cells ( Friesland et al, 2013 ).…”

Section: Likely Mechanisms Of Action In Covid-19mentioning

confidence: 99%

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

et al. 2021

View full text Add to dashboard Cite

Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, through which it controls inflammation. We review here a body of literature that shows important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID-19 treatment. These effects include: reduction in platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, regulation of inositol-requiring enzyme 1α-driven inflammation and increased melatonin levels, which collectively have a direct antiviral effect, regulate coagulopathy or mitigate cytokine storm, which are known hallmarks of severe COVID-19.

show abstract

Section: Likely Mechanisms Of Action In Covid-19mentioning

confidence: 99%

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The two articles published in Nature and Science strongly suggest that the ER chaperone protein sigma-1 receptor plays an important role in the replication of SARS-CoV-2 in cells, and that the sigma-1 receptor is a promising therapeutic target for COVID-19 infection [ 41 , 42 , 44 , 74 , 88 ]. However, which pharmacological activity (i.e., agonist or antagonist) of sigma-1 receptor ligands is responsible for the blockade of SARS-CoV-2 replication remains uncertain.…”

Section: Conclusion and Future Directionmentioning

confidence: 99%

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

Hashimoto

2021

Eur Arch Psychiatry Clin Neurosci

101

115

View full text Add to dashboard Cite

“…The splenium of the corpus callosum is known to be vulnerable to cytotoxicity (8) and lesions in the splenium, particularly in the anterior region, have been reported to be associated with psychiatric symptoms including insomnia, irritability, behavioral changes and psychosis (9) . Viral infections including influenza, adenovirus and rotavirus may be causative factors for corpus callosum damage (8) .…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2-associated first episode of acute mania with psychotic features

Sen

Yeşilkaya

Balcıoğlu

2021

Journal of Clinical Neuroscience

Self Cite

View full text Add to dashboard Cite

Despite neuropsychiatric outcomes of SARS-CoV-2 infection are now under close scrutiny, psychoneuroimmunological characteristics of COVID-19 and precise pathophysiology of neuropsychiatric manifestations of the infection are still obscure. Moreover, there still exists a shortfall in demonstrating specific clinical manifestations of the brain involvement of the virus. Here, we presented a 33-year-old female patient with COVID-19, reporting acute-onset paranoid delusions symptoms, insomnia and irritability. Cranial MRI showed an hyperintense signal in the splenium of the corpus callosum with decreased apparent diffusion coefficient, which might possibly indicate the presence of cytotoxic edema related to the brain involvement of the infection. Following the completion of SARS-CoV-2 treatment, both cytotoxic edema and psychiatric symptoms resolved. In light of this report, we suggest that either heightened immune response and direct viral infection that SARS-CoV-2 may lead to such psychiatric manifestations and neuropsychiatric monitoring should be performed in patients with COVID-19. Prompt recognition of psychiatric consequences of COVID-19 may help clinicians provide guidance for differential diagnosis and manage them accordingly.

show abstract

Reissuing the sigma receptors for SARS-CoV-2

Cited by 13 publications

References 6 publications

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

SARS-CoV-2-associated first episode of acute mania with psychotic features

Contact Info

Product

Resources

About